Oxford Technology & Innovations EIS Fund (OTIF) and co-investors participate in ONI’s $75m Series B financing
- ONI has closed a $75m Series B financing led by US investors ARCH Venture Partners and Casdin Capital.
- ONI is a pioneer in observing single molecules in living cells. The Company’s first product, the Nanoimager, is the world’s first desktop, super-resolution, single-molecule imaging platform capable of visualising and tracking individual molecules in complex systems such as nanoparticles, living cells and tissue with 20nm resolution.
- The Series B funds will be used to build a product portfolio that harnesses the Company’s innovative technology to unlock new possibilities in therapeutic and diagnostic development, as well as basic life sciences research.